ADARx is a clinical-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA therapeutics to treat a broad spectrum of diseases.
Iambic Therapeutics is a clinical-stage biotechnology company specializing in AI-driven drug discovery, recently collaborating with Revolution Medicines to develop novel oncology drug candidates.
We have established a replicable and scalable model for drug discovery and development and are advancing a diversified portfolio of programs with the intention of efficiently delivering safe and effective medicines to patients with autoimmune and inflammatory diseases.
Cardurion is a next-generation cardiovascular company that is taking a bold and innovative approach to addressing the unmet needs of people suffering from and at risk of heart disease.
OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, NASH, and more.
Alpha-9 is a leading, clinical stage radiopharmaceutical company, advancing a distinctive portfolio of molecules. Using targeted, bespoke molecules, we treat cancer cells with unparalleled precision.
© Ascenta Capital 2025. All rights reserved.
